Navigation Links
Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
Date:6/11/2008

SEATTLE and PARIS, June 12 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (Nasdaq: TGEN) announced today that positive results of a Phase 1/2 clinical study demonstrate that tgAAC94, its investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve disease symptoms in inflammatory arthritis patients refractory to other therapies, including systemic TNF antagonists. Full results of the study were presented here today during an oral presentation at the Annual European Congress of Rheumatology (EULAR).

The Phase 1/2 study evaluated multiple doses of tgAAC94 administered directly to affected joints with or without concurrent systemic TNF antagonist therapies. The study achieved its primary endpoint of safety and tolerability.

"We are encouraged by the patient-reported symptom improvement -- early signs of efficacy that indicate further study is warranted," said Philip Mease, M.D., Chief, Rheumatology Clinical Research Division of Swedish Hospital Medical Center and Head of Seattle Rheumatology Associates, who presented the data.

Study Details

127 patients with inflammatory arthritis received a single intra-articular injection of either tgAAC94 or placebo, followed by a second injection 12-30 weeks later depending on when the injected joint met criteria for re-injection. tgAAC94 was well tolerated at all dose levels. Two SAEs of focused interest were reported -- a culture-negative septic arthritis considered probably related to study drug and a fatal disseminated histoplasmosis and retroperitoneal hemorrhage considered not related to study agent. Administration site reactions were observed in 12% of subjects.
'/>"/>

SOURCE Targeted Genetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
2. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
3. Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies
4. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
5. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
6. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
7. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
8. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
9. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
10. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
11. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... "US Self-monitoring Blood Glucose Market" report to ... This market insight focuses on the developments ... the United States . Reimbursement analysis and the ... analyses for more than 73 SMBG meters have been ...
(Date:12/22/2014)... 2014 Cyberonics, Inc. (NASDAQ: CYBX ), ... management of epilepsy, today announced it will participate in the ... January 14, 2015, in San Francisco . ... Executive Officer, will speak at 11:00 AM Pacific Time.  A ... clicking on the Investor Relations link on the Cyberonics home ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... (Nasdaq: NVAX ) a clinical-stage vaccine company, ... of Novavax will be presenting at the Stifel Nicolaus ... 17, 2010 at 10:20am local time at the Four ... company overview, outline its competitive position and characterize Novavax,s ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ... million shares of its common stock pursuant to an effective ... Inc. is the sole book-running manager of the offering and ... to purchase up to 1,245,000 additional shares. Halozyme intends to ...
Cached Medicine Technology:Halozyme Therapeutics Announces Public Offering of Common Stock 2Halozyme Therapeutics Announces Public Offering of Common Stock 3
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping tips ... the models at LunaDress.co.uk come with big discounts, up to 80 ... can turn out to be a most exciting memory and can ... bring surprise to a wedding. On the updated fashion blog, ladies ... for a big day . , Going out with friends to ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
(Date:12/24/2014)... Epigenetics finds applications in a large number ... discovery, developmental biology, and research for metabolic and genetic ... most widely used techniques for the discovery and development ... cancer is rapidly growing worldwide. In 2012, there were ... and 32.6 million people living with cancer (within five ...
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... Inc. (NYSE: MYL ),today announced that its subsidiary, ... and Drug Administration (FDA) for its,Abbreviated New Drug Application ... Zaleplon Capsules are the generic version of King Pharmaceuticals,Sonata(R) ... for,the 12 months ending March 31, 2008, according to ...
... news that DuPont,s Teflon chemicals likely,contaminate area residential wells. ... level., - Private residential well contamination with PFOA ... private drinking water wells and warnings,issued to residents in ... DEEPWATER, N.J., June 9 A coalition of,environmental ...
... ALEXANDRIA, Va., June 9 The National,Community ... of,Compounding Pharmacists (IACP) are collaborating to increase ... engage in compounding.,IACP has established a satellite ... their Director of Public Affairs, Sarah R. ...
... and Good Health this Father,s Day, Nearly 40 Million ... ... 9 Families sick and tired of Dad,s raucous,snoring, incessant allergic ... Snoring Center: a unique medical practice dedicated,exclusively to the evaluation and ...
... A new study demonstrates that microRNAs can modulate the ... may play a significant role in some human cancers. ... issue of the journal Cancer Cell, is likely to ... and leukemias. , MicroRNAs (miRNAs) are small noncoding pieces ...
... way solid tumors adapt the body,s machinery to bring ... these tumors stronger. , "In a sense, these therapies ... D.V.M., Ph.D., professor of radiation oncology at Duke University ... killing many if not most tumor cells, you are ...
Cached Medicine News:Health News:New Jersey Coalition Calls for Investigation of Private Wells to Protect Families from PFOA in Drinking Water 2Health News:New Jersey Coalition Calls for Investigation of Private Wells to Protect Families from PFOA in Drinking Water 3Health News:Pharmacist Associations Partner to Increase the Voice of Pharmacy 2Health News:Stop Dad's Sleepless Nights - and the Sniffles - With the Snoring Center 2Health News:Stop Dad's Sleepless Nights - and the Sniffles - With the Snoring Center 3Health News:MicroRNA controls expression of oncogenes 2Health News:Solid tumor cells not killed by radiation and chemotherapy become stronger 2
Anatomically designed 3 cervical foam collar...
This model utilizes the Malibu Soft Cervical Collar with a Thoracic Extension....
... Occipital Mandibular Immobilizer) A completely adjustable ... or hypertension positioning and immobilization. Offers ... Philadelphia™ collar and a halo-type brace.,Mandibular ... Removable chin plate allows for patient ...
... Wrap® Economy Universal Cervical ... with synthtic white stockinette ... for flexion or extension. ... air dry. 3"H.,Universal size ...
Medicine Products: